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Abstract
Introduction Saliva is a body fluid that holds promise for
use as a diagnostic fluid for detecting diseases. Salivary
proteins are known to be heavily glycosylated and are
known to play functional roles in the oral cavity. We
identified N-linked glycoproteins in human whole saliva, as
well as the N-glycoproteins in parotid, submandibular, and
sublingual glandular fluids.
Materials and Methods We employed hydrazide chemistry
to affinity enrich for N-linked glycoproteins and glycopep-
tides. PNGase F releases the N-peptides/proteins from the
agarose-hydrazide resin, and liquid chromatography–
tandem mass spectrometry was used to identify the salivary
N-glycoproteins.
Results A total of 156 formerly N-glycosylated peptides
representing 77 unique N-glycoproteins were identified in
salivary fluids. The total number of N-glycoproteins identified
in the individual fluids was: 62, 34, 44, and 53 in whole saliva,
parotid fluid, submandibular fluid, and sublingual fluid,
respectively. The majority of the N-glycoproteins were
annotated as extracellular proteins (40%), and several of the
N-glycoproteins were annotated as membrane proteins (14%).
A number of glycoproteins were differentially found in
submandibular and sublingual glandular secretions.
Conclusions Mapping the N-glycoproteome of parotid,
submandibular, and sublingual saliva is important for a
thorough understanding of biological processes occurring in
the oral cavity and to realize the role of saliva in the overall
health of human individuals. Moreover, identifying glyco-
proteins in saliva may also be valuable for future disease
biomarker studies.
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Disease biomarker
Introduction
Glycosylation is a posttranslational modification that plays
an important role in many cellular processes such as protein
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conformation, folding, transport, targeting, and stability [1].
Cell growth, differentiation, cell–cell communication, cel-
lular trafficking, immune response, microbial pathogenesis,
and other biological processes are influenced by glycosyl-
ation [2, 3]. Protein glycosylation is often found to vary
with disease progression [4–6]. It is not surprising to note
that a significant number of known and Food and Drug
Administration-approved biomarkers for diseases are gly-
coproteins [7], including CA 15-3 [8] and c-erb-2 [9] for
breast cancer, prostrate-specific antigen [10] for prostrate
cancer, CA125 [11] for ovarian cancer, and carcinoem-
bryonic antigen for ovarian, prostrate, and colon cancers
[12]. Glycoproteins represent an interesting subproteome that
can be mined to improve the chances for discovering putative
robust, specific, and selective biomarkers for diseases.
Biofluids such as serum/plasma, saliva, and urine are
excellent starting points for such biomarker discovery
studies. Human saliva is gaining popularity as a body fluid
for diagnostic purposes. Its ready availability, ease of
collection, and ease of storage makes it a potential ideal
candidate for use as a diagnostic medium. Whole saliva has
contributions from three primary salivary glands: the
parotid (PA), submandibular (SM), and sublingual (SL)
glands, in addition to other minor contributions (e.g., from
numerous minor glands in the lip, cheek, tongue, and
palate, microbes, epithelial cells, nasal, and bronchial
secretions, and serum products).
Many types of posttranslational modifications have been
observed on salivary proteins [13, 14]. Some of the
common modifications include glycosylation, phosphory-
lation, sulfation, acylation, deamidation, and proteolysis.
Glycosylation is a posttranslational modification that has
important functions in the oral cavity such as lubrication
and protection of oral cavity and teeth from oral pathogens,
chemicals, and mechanical wear and tear. Some of the
salivary glycoproteins involved in lubrication include
proline-rich glycoprotein and mucins. Proline-rich glyco-
proteins are primarily secreted by the PA glands and are N-
glycosylated. The oligosaccharides make up to 50% of their
weight and are responsible for their lubricating properties
[15]. Mucins are also heavily O-glycosylated, which
explains their viscous nature and their profound role in
oral lubrication [16, 17]. The sugars also help mucins bind
to surfaces in the mouth to protect them from chemicals,
wear and tear, and microbes [18]. Other functions of
salivary glycoproteins include binding to oral pathogens
and eliminating them from the oral cavity; proline-rich
glycoproteins, mucins, and salivary agglutinins have an
especially important part in these functions. Proline-rich
glycoproteins bind Fusobacterium nucleatum that causes
periodontal diseases and may be responsible for its
clearance from the mouth [19]. Mucins also bind and
aggregate bacteria such as Heliobacter pylori and flush them
from the oral cavity [20]. Salivary agglutinins efficiently
adhere to and help rid the oral cavity of Streptococcus
mutans [21]. In addition, agglutinins have shown an
influenza A-neutralizing effect [22]. After secretion of saliva
from the salivary glands into the mouth, glycoproteins may
undergo deglycosylation. This might have interesting con-
sequences for oral pathogens and the function of glycopro-
teins. Many bacteria are known to deglycosylate glycoproteins
such as mucins and utilize the released sugars for their
growth [23]. Some Streptococcus species secrete neuramini-
dases that cleave the terminal sialic acid from mucins. This
affects the ability of mucins to bind and aggregate bacteria
such as Streptococcus sanguis [24]. The removal of sialic
acid may also help bacteria bind to sugars on glycoproteins
and colonize in the oral environment [14].
Mapping the salivary glycoproteome will be an impor-
tant step toward using saliva for disease diagnosis. Whole
saliva is far easier to collect compared to ductal saliva, and
whole saliva will likely have more applications for disease
biomarker studies compared to PA, SM, and SL saliva.
However, mapping the N-glycoproteome of PA, SM, and
SL saliva is important for a thorough understanding of
biological processes occurring in the oral cavity and to
realize the role of saliva in the overall health of human
individuals.
Several methods for global glycoprotein profiling of
biofluids have been explored to date, and many of the same
techniques have also been applied to enrich for disease
biomarkers. Some of the common methodologies tested
include lectin affinity purification [25], hydrazide-based
chemical derivatization for glycoprotein capture, and
hydrophilic affinity capture methods. Lectins are a class
of proteins found in plants, bacteria, fungi, and animals that
bind to specific oligosaccharides on glycoproteins [26].
Whereas the use of a single lectin can help to enrich for a
small group of glycoproteins, the use of multiple lectins
increases the chances for isolating a broad spectrum of
glycoproteins. This method, termed multilectin affinity
chromatography, has been used to map glycoproteins in
the plasma and serum [27–29]. To enrich for glycoproteins
to which lectins do not have a strong specificity, the use of
serial lectin affinity chromatography (SLAC) has been
reported [30]. Because there are few reported lectins with
sufficient selectivity for O-linked glycoproteins, SLAC has
been used to isolate and identify O-linked glycopeptides in
human serum [30]. The use of a broad-spectrum lectin such
as concanavilin A was used to deplete N-linked glycopro-
teins and to enrich for O-linked glycoproteins. Jacalin is a
lectin that has affinity for the GalNAc core of O-linked
glycans but also for high mannose-type sugars found in N-
linked glycoproteins. The subsequent application of the N-
glycoprotein-depleted sample to a Jacalin column improved
recovery and identification of O-linked glycoproteins [30].
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Lectin affinity chromatography has also been employed to
search for disease biomarkers in human plasma and serum
[31, 32].
Phenyl boronic acid is considered a pseudolectin because
it covalently attaches to cis-diol containing groups on the
sugars of glycoproteins. This bond is fairly stable under
alkaline conditions. Thus, boronic acids can be utilized to
select for a broader group of glycoproteins including N-,
O-, and C-linked glycoproteins. Lectins and boronic acid
can be combined in a single experiment to enrich for
glycoproteins [33]. Sparbier and coworkers used a combi-
nation of lectin and boronic acid magnetic beads to affinity
select glycoproteins from human serum [34].
Hydrophilic affinity-based capture methods have been
extended to isolate glycoproteins from complex mixtures.
Because sugars are very hydrophilic, glycoproteins lend
themselves well to being captured onto a hydrophilic
stationary phase. Several hydrophilic materials have been
tested in the past. Some of them include carbohydrate gel
matrices such as sepharose and cellulose and hydrophilic
interaction chromatography (HILIC) columns. Cellulose
and sepharose matrices were successfully employed to
isolated glycoproteins from human serum [35]. HILIC
using a resin containing a polyhydroxyethyl aspartamide
group has been used to separate sialylated glycopeptides
from recombinant human interferon-γ [36]. Hagglund and
coworkers used a resin with a covalently bound neutral,
zwitterionic sulfobetaine functional group to perform
zwitterion chromatography–HILIC (ZIC-HILIC). Glyco-
peptides were separated via ZIC-HILIC from nonglycopep-
tides in trypsin digest mixtures and were then partially
deglycosylated to identify glycoproteins in human plasma
[37, 38].
Larsen and coworkers published an elegant method to
isolate sialic acid-containing glycoproteins in plasma and
whole saliva. Their method employs titanium dioxide,
which has an affinity for acidic groups. TiO2 has been
used commonly to purify and measure phosphoproteins
[39]. However, it also binds to sialic acid-containing
glycoproteins. After removing phospho-groups on phos-
phopeptides by alkaline phosphatase treatment, the peptide
mixture was passed through the TiO2 column to isolate
sialated glycopeptides, and the glycopeptides were ana-
lyzed subsequently by mass spectrometry (MS). Using this
method, sialated proteins in plasma and whole saliva were
identified [40].
Zhang and coworkers published a landmark paper
describing the isolation of formerly N-linked glycopeptides
from complex mixtures using hydrazide chemistry [41].
This method has gained popularity over the past few years.
Sugars on glycoproteins are first oxidized and immobilized
onto an agarose–hydrazide resin. The resin is then washed
to remove nonspecifically bound proteins. The proteins
bound to the resin are digested with trypsin, and tryptic
peptides not covalently bound to the column are removed
by extensive washing. The bound tryptic N-glycopeptides
are then released using the enzyme PNGase F, and the
formerly N-glycosylated peptides are analyzed by MS. The
identification of the formerly N-glycosylated peptide is
confirmed by the presence of an N–X–S/T motif on the
peptide sequence (where X denotes any amino acid residue
except proline) and the conversion of asparagines at the site
for glycosylation to aspartic acid resulting in a mass
increase of +1 Da. This method has since been widely
applied toward the study of the N-glycoproteome of various
human body fluids including plasma [42], serum [43],
whole saliva [44], and cerebrospinal fluid [45]. In 2007,
two independent groups published slightly modified ver-
sions of the original method described by Zhang et al. [41].
The similarity between the two methods was that the
proteins initially were digested to tryptic peptides before
being coupled onto the agarose–hydrazide resin. In the
method published by Sun et al., excess sodium periodate,
used to oxidize sugars on glycopeptides, was quenched
with sodium sulfite. The method was used to identify
unique proteins from microsomal fractions of the cisplatin-
resistant ovarian cancer cell lines [46]. Alternately, Tian et
al. removed remaining sodium periodate by desalting the
oxidized glycopeptides using a C18 column [47]. This
technique was successfully used to isolate N-linked
glycopeptides from mouse plasma including some proteins
that are found in low abundance in human plasma [48].
There are also differences in the wash step to remove
nonspecifically bound peptides from the agarose–hydrazide
resin, but the basic outline of the two procedures remains
similar.
Our group previously reported, using the method of
Zhang et al. [41], a global N-glycoproteome analysis of
whole-saliva proteins using the hydrazide capture technique
and MS, identifying 84 formerly N-glycosylated peptides
from 45 glycoproteins [44]. Larsen et al. used the TiO2
enrichment strategy to isolate the whole salivary sialome
and identified 97 sites of N-linked glycosylation [40]. In
this paper, we extend the salivary glycoprotein catalogue
using the modified hydrazide capture method of Sun et al.
[46], i.e., the capture of tryptic N-glycopeptides and MS
measurement of formerly N-linked glycopeptides. In
addition, we compare for the first time the N-linked
glycoproteins identified in PA, SM, and SL saliva.
Materials and Methods
Chemicals and Reagents The chemicals were mostly
purchased from Sigma (St. Louis, MO, USA), unless stated
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otherwise. Affigel Hz hydrazide gel, coupling buffer, and
dithiothreitol (DTT) were obtained from Bio-Rad (Hercu-
les, CA, USA). Tris-(2-carboxyethyl)-phosphine (TCEP)
and trifluoroacetic acid (TFA) were obtained from Pierce
(Rockford, IL, USA). Glycerol-free PNGase F was
obtained from New England Biolabs (Ipswich, MA,
USA). Sequencing-grade trypsin was procured from Prom-
ega (Madison, WI, USA).
Saliva Collection Whole saliva was collected from healthy
nonsmoking adults in the morning, at least 2 h after the last
intake of food. The mouth was rinsed with water immedi-
ately before the collection. Whole saliva was collected and
placed on ice. Protease cocktail inhibitor (1 μL/mL of
whole saliva) was added to saliva immediately after
collection to minimize protein degradation. Whole saliva
was then centrifuged at 12,000 rpm at 4°C for 10 min. The
supernate was collected and stored at −80°C. The pellet was
saved for future analysis.
For collecting PA, SM, and SL saliva, 10 adult subjects
of various ethnic and racial backgrounds, ranging in age
from 22 to 30 years, were recruited. Saliva collection took
place on a monthly basis and was performed between the
hours of 9 and 11 A.M. Stimulated PA, SM, and SL saliva
were collected by the repeated application of an aqueous
citric acid solution (2%). PA saliva was obtained as the
ductal secretion by using a cup-like device [49]. Separate
SM and SL secretions were acquired by using a saliva
collector, described by Wolff and coworkers, that was fitted
with a sterile 100-μL-pipette tip [50]. Collection volumes
over a 10-min period ranged from 500 to 2,000 μL for PA
saliva, 50 to 100 μL for SL saliva, and 100 to 500 μL for
SM saliva. PA, SM, and SL saliva from five subjects were
pooled before carrying out the experiments.
Solution Isoelectric Focusing Fractionation The procedure
for solution isoelectric focusing (IEF) fractionation has
been described previously [44]. Briefly, proteins in whole
saliva were precipitated by mixing with four times the
volume of cold ethanol and incubating at −20°C overnight.
The mixture was centrifuged at 13,000 rpm for 15 min at
4°C. The pellet was resuspended in Zoom 2D protein
solubilizer (Invitrogen, Carlsbad, CA, USA), protease
inhibitor (Roche Diagnostic, Indianapolis, IN, USA), Tris
base, DTT, and water and sonicated on ice. The pH of the
solution was adjusted to pH 8.5–8.7 with 1 M Tris base and
then incubated for 15 min at room temperature with
shaking. Proteins were alkylated with 99% dimethylacryla-
mide (DMA) at room temperature for 30 min, as suggested
by the protocols from Invitrogen. To quench excess DMA,
DTT was added and incubated at room temperature for
5 min. After centrifuging the sample for 30 min at
13,400 rpm at 4°C, the supernate was collected. The
protein concentration was determined by the noninterfering
protein assay (Geno Technology, St. Louis, MO, USA).
The concentration was measured to be approximately
1.5 mg/mL.
The solution of proteins in the Zoom-2D solubilizer
(1.5 mg/mL, 400 μL) was diluted to a final concentration of
0.6 mg/mL in diluted buffer (Zoom IEF denaturant, Zoom
focusing buffer pH 3–7, Zoom focusing buffer, pH 7–12,
and 5 μL 2M DTT). Zoom IEF fractionation was performed
in the standard format (pH 3.0 to 10). The diluted sample
was loaded into each of the five chambers of the
fractionator and subjected to solution-phase IEF. Five
fractions (pI 3–4.6, 4.6–5.4, 5.4–6.2, 6.2–7.0, and 7.0–
10.0) were obtained after the procedure. Proteins from each
fraction were precipitated by mixing with 70% acetone,
incubating at −20°C for 3–4 h, and centrifuging at
13,000 rpm for 30 min.
Glycoprotein Enrichment Proteins from saliva that were not
previously pI fractionated were isolated by precipitation
using ethanol. Proteins from Zoom IEF-separated fractions
were obtained by acetone precipitation. The salivary
proteins isolated by either method were resuspended in
coupling buffer (100 mM sodium acetate, 150 mM sodium
chloride, pH 5.5). Sodium periodate was added to a final
concentration of 15 mM. The solution was incubated in the
dark at room temperature for 1 h. Glycerol was added to a
final concentration of 20 mM to quench any excess sodium
periodate remaining in the solution. The mixture was
incubated for 15 min with mixing at room temperature.
To remove remaining sodium periodate, the solution was
dialyzed using a 3.5-kDa dialysis cassette against 1×
coupling buffer at 4°C overnight. The hydrazide resin was
equilibrated by washing with 3 vol of water and 6 vol of
coupling buffer. The proteins were added to the resin and
coupled overnight by incubating overnight at room tem-
perature with shaking. The resin was then allowed to settle,
and the supernate containing uncoupled nonglycoproteins
was discarded. The resin was washed six times with urea
buffer A containing 8 M urea, 200 mM Tris, 0.05% sodium
dodecyl sulfate, and 5 mM ethylenediamine tetraacetic acid
(pH 8.3). The proteins on the resin were reduced with a
solution of 10 mM TCEP in urea buffer A. The reduced
proteins were alkylated with 50 mM iodoacetamide in urea
buffer. The resin was then washed six times with urea
buffer B (1 M urea, 25 mM Tris, pH 8.3). The resin was
resuspended in urea buffer B. Trypsin was added to the
solution, and the proteins attached to the resin were
digested at 37°C overnight with shaking. The nonglyco-
peptides released by trypsin digestion were removed by
washing three times with 1.5 M NaCl, 80% acetonitrile
(ACN)/0.1% TFA, methanol, and water and six times with
100 mM ammonium bicarbonate. The resin was resus-
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pended in 100 mM ammonium bicarbonate. The N-linked
glycopeptides were released by adding PNGase to the resin
and incubating at 37°C overnight. The resin was washed
twice with 80% ACN solution. The washes were combined,
and the released glycopeptides were dried by vacuum
centrifugation. The peptides were then resuspended in 0.1%
formic acid (FA) and analyzed by one-dimensional (1D)
liquid chromatography (LC)–MS/MS.
Glycopeptide Enrichment The method used followed that
described by Sun et al. [46]. Proteins from whole saliva,
PA, SM, and SL saliva were precipitated using cold
ethanol. The pellets were resuspended in 50 mM ammoni-
um bicarbonate buffer (pH 7.8) with sonication. TCEP was
added to a final concentration of 10 mM at room
temperature to reduce disulfide bonds (TCEP is preferred
over DTT in this case because elevated temperatures
required by DTT–disulfide reduction often causes protein
precipitation from salivary fluids). The solution was
incubated at room temperature for 30 min with shaking.
Iodoacetamide (50 mM) was added to alkylate the reduced
cysteines, and the mixture was incubated at room temper-
ature for 30 min with shaking. Afterwards, DTT (25 mM)
was added to the solution to quench any remaining
unreacted iodoacetamide. The mixture was incubated at
room temperature for 30 min. Trypsin was added (1:50 by
weight) to digest the proteins in solution, and the solution
was incubated at 37°C overnight. The tryptic peptide
mixture was then acidified with FA to bring the pH below
4.0. The tryptic peptides were desalted using a C18 Sep-
Pak reverse-phase (RP) column (Waters, Milford, MA,
USA). Peptides were then dried and resuspended in
coupling buffer (100 mM sodium acetate, 150 mM sodium
chloride, pH 5.5). Sodium periodate was added to a final
concentration of 10 mM to oxidize cis-diol groups on
sugars. The mixture was incubated in the dark at room
temperature for 1 h. Any remaining unreacted sodium
periodate was quenched with sodium sulfite to a final
concentration of 20 mM. The solution was incubated at
room temperature for 10 min. The mixture was then added
to agarose–hydrazide resin to couple the peptides to the
resin, and the coupling reaction was allowed to proceed
overnight at room temperature. The agarose-hydrazide resin
was transferred to a Handee minispin column (Pierce,
Rockford, IL, USA) and washed with 1.5 M NaCl, 80%
ACN, methanol, water, and freshly prepared 100 mM
ammonium bicarbonate solution. The resin was incubated
overnight at 37°C with PNGase F in 100 mM ammonium
bicarbonate to release formerly N-glycosylated peptides.
Afterwards, the resin was washed twice with 80% ACN
solution. The washes were combined, and the released
glycopeptides were dried in the vacuum centrifuge. The
formerly N-glycosylated peptides were then resuspended in
1% FA and analyzed by 1D- and two-dimensional (2D) LC-
MS/MS.
Liquid Chromatography–Tandem Mass Spectrometry LC-
MS/MS and 2D LC-MS/MS were performed on a QSTAR
XL (QqTOF) mass spectrometer (Applied Biosystems,
Foster City, CA, USA) equipped with a nanoelectrospray
(Protana, Odense, Denmark) interface and an LC Packings/
Dionex (Sunnyvale, CA, USA) nano-LC system.
For 1D LC-MS/MS, the nano-LC was equipped with a
set of homemade precolumns (75 μm×10 mm) and a
column (75 μm×150 mm) packed with Jupiter Proteo C12
resins (particle size 4 μm, Phenomenex, Torrance, CA,
USA). The peptides were dried and redissolved in 0.1% FA
solution. For each LC-MS/MS run, typically, 6 μL sample
solution was loaded onto the precolumn. The precolumn
was washed with the loading solvent containing 0.1% FA
for 4 min before the sample was injected onto the LC
column. The eluents used for the LC were water containing
0.1% FA (A) and 95% ACN/water containing 0.1% FA (B).
The flow was 200 nL/min. The following analytical LC
gradient was used for analyzing the formerly N-glycosylated
peptides obtained by the glycopeptide enrichment method: 3–
21% B for 36 min, 21–35% B for 14 min, and 36–80% B for
4 min and held at 80% B for 10 min. The column was
equilibrated with 3% B for 16 min before the next run. The
gradient used for analyzing formerly N-glycosylated peptides
obtained by the glycoprotein enrichment method was 3–35%
B for 72 min and 35–80% B for 18 min and maintained at
80% B for 9 min.
For the online 2D LC-MS/MS, 20 μL of sample solution
was loaded onto a strong cation exchange (SCX) precol-
umn (Luna SCX resin, particle size 5 μm, 150 μm×5 mm,
Phenomenex) before transfer to a RP precolumn (Jupiter
Proteo C12 resin, particle size 4 μm, 150 μm×5 mm,
Phenomenex) and RP analytical column (Jupiter Proteo
C12 resin, particle size 4 μm, 75 μm×150 mm, Phenom-
enex). Seven concentrations of ammonium acetate solutions
(50, 100, 200, 400, 600, 1,000, and 2,000 mM) were
injected (4 μL) onto the SCX precolumn for the step
gradient elution of peptides.
The RP precolumn was used to preconcentrate and desalt
each peptide fraction eluted from the SCX column prior to
nano-RP LC separation. SCX fractions were loaded onto
the RP precolumn with the following gradient: 3% B for
6 s, 6–24% B for 18 min, 24–36% B for 6 min, and 36–
80% B for 2 min and maintained at 80% B for 8 min. The
column was equilibrated with 3% B for 15 min prior to the
next run. SCX fractions were separated on the analytical RP
column (200 nL/min) with the following gradient: 3% B
for 5 min, 3–6% B for 6 s, 6–24% B for 18 min, 24–36% B
for 6 min, and 36–80% B for 2 min and held at 80% B for
8 min.
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For online MS/MS analyses, a Proxeon nanobore
stainless steel online emitter (inner diameter=30 μm) was
used for electrospraying with the voltage set to 1,900 V.
Peptide product ion mass spectra were recorded during LC-
MS/MS by information-dependent analysis on the QSTAR
XL mass spectrometer. Argon was employed as the
collision gas. Collision energies for maximum fragmenta-
tion were automatically calculated using empirical param-
eters based on the charge and mass-to-charge ratio of the
precursor peptide.
Protein identification was accomplished utilizing the
Mascot database search engine (Matrix Science, London,
UK). For search the sequence databases, the following
variable modifications were set: carbamidomethylation of
cysteines, oxidization of methionines and enzyme-catalyzed
conversion of asparagines to aspartic acid at the site of
carbohydrate attachment on asparagines, conversion of N-
terminal glutamate and aspartate to pyro-Glu, and cycliza-
tion of N-terminal cysteine. DMA modification of cysteine
was set as one of the parameters in experiments where
Zoom IEF fractionation had been done prior to glycoprotein
pulldown. Searches for peptides obtained by the glycopro-
tein enrichment method were performed against the Human
IPI database. For the searches, one missed tryptic cleavage
was tolerated, and the peptide and MS/MS mass tolerance
was set as 0.3 Da. A Mascot score of greater than 20 was
considered a significant match. All matching peptide MS/
MS spectra were manually examined to verify the accuracy
of the identification. Positive protein identification was
based on standard Mascot criteria for statistical analysis of
the LC-MS/MS data. For samples obtained by the glyco-
peptide enrichment method, searches were done against the
Human IPI database (version 3.39) and its reverse decoy
database. Only peptides above Mascot’s homology or
identity threshold were considered. The validity of the
formerly N-glycosylated peptides were confirmed by the
presence of a consensus N–X–(S/T) where X is any amino
acid except proline and the conversion of asparagines to
aspartic acid at the site of former N-glycosylation resulting
in a mass change of +1 Da. With MS/MS tolerances set to
0.3 Da, a 1-Da difference caused by deamidation of Asn to
Asp is readily detected from measurements performed on
the QTOF mass spectrometer.
Results
Isolation of N-linked Glycoproteins In our previous study
on salivary N-linked glycoproteins [44], we used the
agarose–hydrazide glycoprotein pulldown technique of
Zhang et al. [41] to characterize human whole saliva (we
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Fig. 1 Steps involved in the
isolation of formerly
N-glycosylated peptides using
the a Zhang method and b the
Sun method
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Table 1 Comparison of N-linked glycoproteins identified in whole saliva using the Zhang method and the Sun method
IPI Accession
number
















IPI00002818 Splice isoform 1 of kallikrein 11 27,448 CAN*ITIIEHQK No Yes (35) – 0
IPI00003351 Extracellular matrix protein 1 60,635 HIPGLIHN*MTAR No Yes (43) – 0
IPI00004573 Polymeric-immunoglobulin receptor 83,232 VPGN*VTAVLGETLK Yes (101) Yes (113) 18 3
WNN*TGCQALPSQDEGPSK Yes (72) Yes (62)
IIEGEPNLKVPGN*VTAVLGETLK Yes (49) Yes (112)
LSLLEEPGN*GTFTVILNQLTSR Yes (60) Yes (99)
ANLTNFPEN*GTFVVNI
AQLSQDDSGR
Yes (70) Yes (108)
QIGLYPVLVIDSSGYVNPN*YTGR Yes (95) Yes (112)
VPGN*VTAVLGETLKVPCHFPCK No Yes (50)
IPI00007244 Myeloperoxidase 83,815 SCPACPGSN*ITIR Yes (46) No 2 –
SYN*DSVDPR Yes (41) No
IPI00011229 Cathepsin D 44,524 GSLSYLN*VTR No Yes (49) – 0
IPI00855918 Mucin 5, subtype B, tracheobronchial 590,122 VVLLDPKPVAN*VTCVNK Yes (60) Yes (80) 37 0
AQGLVLEASN*GSVLINGQR Yes (118) Yes (120)
GN*CTYVLMR Yes (32) Yes (39)
AFGQFFSPGEVIYN*K No Yes (72)
AFGQFFSPGEVIYN*KTDR Yes (49) Yes (72)
DIECQAESFPN*WTLAQVGQK Yes (82) Yes (86)
QVNETWTLEN*CTVAR Yes (47) Yes (67)
LDGPTEQCPDPLPLPAGN*
CTDEEGICHR




LPYSLFHN*NTEGQCGTCTNNQR Yes (32) No
IPI00012887 Cathepsin L 37,540 YSVAN*DTGFVDIPK No Yes (57) – 0
IPI00013972 Carcinoembryonic antigen-related cell
adhesion molecule 8
38,130 LFIPN*ITTK Yes (47) No 0 –
IPI00019943 Afamin 69,024 DIENFN*STQK Yes (41) No 0 –
IPI00020091 Alpha-1-acid glycoprotein 2 23,588 QNQCFYN*SSYLNVQR Yes (90) No 0 –
IPI00020487 Extracellular glycoprotein lacritin 14,237 QFIEN*GSEFAQK Yes (32) No 1 –
IPI00020986 Lumican 38,405 LHINHNN*LTESVGPLPK No Yes (59) – 0
IPI00021891 Splice Isoform 1 of Fibrinogen
gamma chain
51,479 DLQSLEDILHQVEN*K No Yes (58) – 0
VDKDLQSLEDILHQVEN*K No Yes (70)
IPI00022395 Complement component C9 63,133 AVN*ITSENLIDDVVSLIR No Yes (56) – 0
IPI00022417 Leucine-rich alpha-2-glycoprotein 38,944 KLPPGLLAN*FTLLR Yes (62) Yes (72) 1 0
IPI00022429 Alpha-1-acid glycoprotein 1 24,777 QDQCIYN*TTYLNVQR Yes (105) No 0 –
IPI00022431 Alpha-2-HS-glycoprotein 39,300 AALAAFNAQNN*GSNFQLEEISR Yes (64) Yes (26) 1 –
VCQDCPLLAPLN*DTR Yes (40) No
IPI00022463 Serotransferrin 77,000 CGLVPVLAENYN*K No Yes (69) 9 0
QQQHLFGSN*VTDCSGNFCLFR Yes (62) No
IPI00022488 Hemopexin 51,643 ALPQPQN*VTSLLGCTH Yes (56) Yes (58) 1 0
SWPAVGN*CSSALR Yes (47) No
IPI00022974 Prolactin inducible protein 16,562 TFYWDFYTN*R Yes (50) No 5 –
IPI00023673 Galectin-3 binding protein 65,289 ALGFEN*ATQALGR Yes (83) Yes (80) 2 0
AAIPSALDTN*SSK Yes (64) Yes (70)
GLN*LTEDTYKPR No Yes (49)
EPGSN*VTMSVDAECVPMVR No Yes (41)
TVIRPFYLTN*SSGVD Yes (57) No
YKGLN*LTEDTYKPR Yes (50) No
IPI00025023 Lactoperoxidase 80,237 KPSPCEFIN*TTAR Yes (34) Yes (53) 8 0
IVGYLNEEGVLDQN*R Yes (77) Yes (89)























IPI00025753 Desmoglein 1 113,644 TGEIN*ITSIVDR Yes (36) No 0 –
IPI00025846 Splice isoform 1 of desmocollin-2 99,899 NGIYN*ITVLASDQGGR No Yes (88) 1 0
AN*YTILK Yes (49) Yes (48)
AN*YTILKGNENGNFK Yes (26) No
LKAIN*DTAAR Yes (31) No
IPI00027412 Carcinoembryonic antigen-related cell
adhesion molecule 6
37,214 LQLSNGN*MTLTLLSVK Yes (63) No 0 –
IPI00027486 Carcinoembryonic antigen-related cell
adhesion molecule 5
76,748 TLTLFN*VTR Yes (42) No 0 –
IPI00031019 Cystatin-related epididymal
spermatogenic protein
16,265 KLKPVN*ASNANVK Yes (43) No – –
IPI00031121 Carboxypeptidase E 53,117 DLQGNPIAN*ATISVEGID
HDVTSAK
No Yes (69) – 0
GN*ETIVNLIHSTR No Yes (43)
IPI00031547 Desmoglein 3 107,435 NTGDIN*ITAIVDR No Yes (80) 0 0
LPAVWSITTLN*ATSALLR Yes (39) No
DSTFIVN*K Yes (45) No
IPI00032258 Complement C4 192,650 GLN*VTLSSTGR Yes (59) Yes (56) 0 0
IPI00032292 Metalloproteinase inhibitor 1 23,156 FVGTPEVN*QTTLYQR Yes (88) Yes (101) 2 –
SHN*RSEEFLIAGK Yes (29) No
IPI00060143 Protein FAM3D 24,947 GLNIALVN*GTTGAVLGQK Yes (56) Yes (83) 0 0
IPI00166729 Alpha-2-glycoprotein 1, zinc 34,223 DIVEYYNDSN*GSHVLQGR Yes (91) Yes (102) 13 0
FGCEIENN*R Yes (57) No
FGCEIENN*RSSGAFWK Yes (58) No
IPI00171411 Golgi membrane protein 1 49,768 AVLVNN*ITTGER Yes (80) Yes (68) 1 0
LQQDVLQFQKN*QTNLER No Yes (56)
IPI00178926 Immunoglobulin J chain 18,087 EN*ISDPTSPLR Yes (55) Yes (75) 6 0
IIVPLNNREN*ISDPTSPLR Yes (56) Yes (68)
IPI00218460 Isoform 3 of attractin 153,687 IDSTGN*VTNELR No Yes (59) – 0
IPI00242956 Fc fragment of IgG binding protein 571,718 VVTVAALGTN*ISIHKDEIGK No Yes (53) 11 1
VITVQVAN*FTLR Yes (58) Yes (50)
VTVRPGESVMVN*ISAK No Yes (54)
KVTVRPGESVMVN*ISAK No Yes (34)
YLPVN*SSLLTSDCSER Yes (98) Yes (46)
IPI00291410 Isoform 1 of long palate, lung, and
nasal epithelium carcinoma-
associated protein 1
54,878 DHN*ATSILQQLPLLSAMR No Yes (87) – 0
GDQLILNLNN*ISSDR No Yes (87)
IPI00291488 Splice isoform of WAP four-disulfile
core domain protein 2
12,984 TGVCPELQADQN*CTQECVS
DSECADNLK
Yes (94) No 0 –
IPI00295105 Carbonic anhydrase VI 35,343 LENSLLDHRN*K No Yes (38) – 0
IPI00296099 Thrombospondin 1 129,330 VVN*STTGPGEHLR Yes (44) No 0 –
IPI00296654 Bactericidal permeability-increasing
protein-like 1
49,100 LGATPVAMLHTNN*ATLR Yes (39) Yes (71) 5 0
LLAAAN*FTFK Yes (64) Yes (66)
SDDNLLN*TSALGR Yes (81) No
IPI00297910 Tumor-associated calcium signal
transducer 2
35,687 HRPTAGAFN*HSDLDAELR No Yes (34) – 0
IPI00298082 Calcium-activated chloride channel
protein 2
101,283 DSFDDALQVN*TTDLSPK Yes (38) No 0 –
IPI00298237 Tripeptidyl-peptidase I 61,708 FLSSSPHLPPSSYFN*ASGR No Yes (65) – 0
IPI00298828 Beta-2-glycoprotein I 38,273 VYKPSAGN*NSLYR Yes (40) Yes (74) 0 0
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will henceforth refer to this technique as the “Zhang
method”). Proteins from whole saliva were isolated in two
different ways. In the first method, proteins in whole saliva
were precipitated with ethanol, and glycoprotein pulldown
proceeded thereafter. The second method involved the
preseparation of proteins into five different pI fractions of
3–4.6, 4.6–5.4, 5.4–6.2, 6.2–7, and 7–10, by solution IEF
fractionation. The proteins in each pI fraction were then
precipitated using acetone. The steps employed for glyco-
protein pulldown in our previous study using the Zhang
method were: (a) resuspending whole salivary proteins in
the coupling buffer, (b) oxidizing saccharides on the
glycoproteins with sodium periodate, (c) quenching excess
sodium periodate with glycerol and removing any remain-
ing sodium periodate by dialyzing against coupling buffer,
(d) coupling glycoproteins to the agarose–hydrazide resin,
(e) washing nonglycosylated proteins, (f) digesting proteins






















22,774 EDKSYN*VTSVLFR Yes (28) No 3
SYN*VTSVLFR Yes (55) No
IPI00299729 Transcobalamin I 48,164 ADEGSLKN*ISIYTK Yes (50) Yes (51) 3 0
MN*DTIFGFTMEER Yes (32) Yes (81)
AQKMN*DTIFGFTMEER Yes (49) No
IPI00300786 Alpha-amylase, salivary 57,731 NVVDGQPFTNWYDN*
GSNQVAFGR
Yes (108) Yes (129) 16 9









IPI00328960 Similar to carcinoembryonic antigen-
related cell adhesion molecule 1
91,568 FVTAGSN*VTLR No Yes (31) – 0
IPI00553177 Alpha-1-antitrypsin 48,208 YLGN*ATAIFFLPDEGK No Yes (100) – 0
IPI00328960 Predicted: hypothetical protein
XP_085831
91,568 TPASN*ISTQVSHTK Yes (44) No 0 –
IPI00333140 Delta notch-like EGF repeat
containing transmembrane
78,438 LVSFEVPQN*TSVK Yes (43) Yes (40) 1 –
IPI00335356 IGHM protein 49,526 GLTFQQN*ASSMCVPDQDTAIR No Yes (40) – 0
IPI00374315 Uncharacterized protein C6orf58 37,902 IILN*QTAR Yes (52) Yes (5) 1 0
MGMYKIILN*QTAR Yes (72) Yes (63)
IPI00419215 Alpha-2-macroglobulin-like protein 1 78,438 LGHIN*FTISTK No Yes (35) – 0
IPI00641229 Ig alpha-2 chain C region 56,111 LAGKPTHVN*VSVVMA
EVDGTCY




TPLTAN*ITK Yes (57) No
IPI00400826 Clusterin 57,796 LAN*LTQGEDQYYLR Yes (64) Yes (88) 0 0
IPI00418512 DMBT1 259,409 LVNLN*SSYGLCAGR Yes (95) Yes (89) 3 0
QADN*DTIDYSNFLTA
AVSGGIIK
Yes (110) Yes (112)
CSGN*ESYLWSCPHK Yes (38) No
IPI00431645 HP protein 31,362 NLFLN*HSEN*ATAK Yes (59) Yes (63) 3 0




IPI00168728 FLJ00385 protein (fragment) 56,075 EEQFN*STFR No Yes (51) – 0
IPI00550991 Alpha-1-antichymotrypsin 50,596 FN*LTETSEAEIHQSFQHLLR No Yes (52) – 0
a N* indicates the site of former N-linked glycosylation
bMascot score listed in parentheses
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away the nonglycopeptides, (h) releasing the formerly N-
glycosylated proteins from the hydrazide resin with
PNGase F, and (i) identifying the formerly N-glycopeptides
by 1D LC-MS/MS (Fig. 1a). A total of eight repetitions
were performed for the glycoprotein pulldown experiments
where saliva proteins were previously precipitated by
ethanol precipitation. Five repetitions of the IEF fraction-
ation followed by glycoprotein pulldown were performed.
In this current study, we applied a modified version of
the glycoprotein pulldown method [46] to extend our
catalogue of whole-saliva N-linked glycoproteins and
developed a new catalogue of N-glycoproteins from
segregated PA, SM, and SL fluids (we will refer to this
modified technique as the “Sun method” in this paper). The
new method entails proteolytic digestion of proteins prior to
coupling to the agarose–hydrazide resin. The other differ-
ence lies in that after the oxidation of sugars, any unreacted
sodium periodate is quenched with sodium sulfite. This
obviates the need to remove sodium periodate by dialysis or
using a desalting column as performed in the previous
study. In this current study, the salivary proteins were
precipitated using ethanol. Thus, the steps to isolate N-
glycoproteins are: (a) resuspending salivary proteins in
ammonium bicarbonate buffer, (b) digesting proteins with
trypsin, (c) desalting the tryptic peptides using a C18
column, (d) oxidizing sugars on glycopeptides with sodium
periodate, (e) quenching any remaining sodium periodate
with sodium sulfite, (f) coupling glycopeptides onto the
agarose–hydrazide column, (g) washing away nonglyco-
peptides, (h) releasing formerly N-linked glycopeptides
with PNGase F, and (i) identifying formerly N-linked
glycopeptides using 1D and 2D LC-MS/MS (Fig. 1b). A
total of eight 1D LC-MS/MS runs were carried out. Some
of the samples were combined, and four additional 2D LC-
MS/MS experiments were performed. Data obtained from
both 1D and 2D LC-MS/MS runs were combined. In both
methods, the formerly N-glycosylated peptide identifica-
tions were validated by the presence of the consensus N–
X–(S/T) motif and conversion of asparagines to aspartic
acid at the site of N-glycosylation. We applied the Sun
method to identify N-glycoproteins in whole saliva, PA,
SM, and SL saliva.
Identification of N-Glycoproteins in Whole Saliva In our
previous study on N-linked glycoproteins in human whole
saliva, we reported 84 formerly N-linked glycopeptides
from 44 unique N-glycoproteins (Table 1) [44]. Using
the newer Sun method, we identified 80 formerly N-
glycosylated peptides from 46 unique N-linked glycopro-
teins (Table 1). However, comparing our previously
identified N-glycoproteins using the Zhang method and
new data set obtained by the Sun method, we found that 42
formerly N-glycosylated peptides from 28 N-glycoproteins
were identified by both methods, 42 formerly N-glycosy-
lated peptides from 16 N-glycoproteins were identified by
the Zhang method uniquely, and 38 formerly N-glycopep-
tides from 18 N-glycoproteins were identified uniquely by
the Sun method. Combining all of the N-glycoproteins
identified by both methods, we have thus far identified
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(a) (b)Glycopeptides GlycoproteinsFig. 2 Comparison of a former-ly N-glycosylated peptides and
the b N-glycoproteins they
represent identified in whole
saliva using the Zhang method
and the Sun method. c
MS/MS mass spectrum of a
doubly charged peptide,
GDQLILNLNN*ISSDR (m/z
837; asterisk denotes the site of
N-glycosylation), from isoform
1 of long palate, lung, and nasal
epithelium carcinoma
(PLUNC)-associated protein 1
measured from whole saliva
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Table 2 N-linked glycoproteins identified in parotid salivary fluid
IPI accession
number


















IPI00011229 Cathepsin D 44,524 GSLSYLN*VTR 68 0
IPI00012887 Cathepsin L 37,540 YSVAN*DTGFVDIPKQEK 42 0
IPI00017601 Ceruloplasmin 122,128 EN*LTAPGSDSAVFFEQGTTR 69 0
EHEGAIYPDN*TTDFQR 49
IPI00021891 Splice Isoform 1 of Fibrinogen
gamma chain
51,479 VDKDLQSLEDILHQVEN*K 53 0
IPI00022417 Leucine-rich alpha-2-glycoprotein 38,944 KLPPGLLAN*FTLLR 78 0
IPI00022431 Alpha-2-HS-glycoprotein 39,300 AALAAFNAQNN*GSNFQLEEISR 113 0
VCQDCPLLAPLN*DTR 50
IPI00022463 Serotransferrin 77,000 QQQHLFGSN*VTDCSGNFCLFR 100 0
CGLVPVLAENYN*K 53
IPI00022488 Hemopexin 51,643 ALPQPQN*VTSLLGCTH 73 0












IPI00032258 Complement C4-A 192,650 GLN*VTLSSTGR 57 0
IPI00032292 Metalloproteinase inhibitor 1 23,156 FVGTPEVN*QTTLYQR 95 0
IPI00032328 Splice Isoform 1 Of Kininogen 71,900 LNAENN*ATFYFK 71 0
IPI00168728 FLJ00385 Protein (Fragment) 56,111 EEQFN*STFR 51 0
IPI00178926 Immunoglobulin J chain 18,087 EN*ISDPTSPLR 63 0
IIVPLNNREN*ISDPTSPLR 57
IPI00291262 Clusterin 52,461 LAN*LTQGEDQYYLR 95 0
MLN*TSSLLEQLNEQFNWVSR 96
IPI00291410 Isoform 1 of long palate, lung,
and nasal epithelium carcinoma-
associated protein 1
52,408 DHN*ATSILQQLPLLSAMR 33 0
IPI00295105 Carbonic anhydrase VI 35,343 GLN*MTGYETQAGEFPMVNN
GHTVQIGLPSTMR
41 0
IPI00296099 Thrombospondin 1 129,330 VVN*STTGPGEHLR 52 0
IPI00296654 Bactericidal/permeability-
increasing protein-like 1
49,100 LGATPVAMLHTNN*ATLR 73 0
IPI00298497 Fibrinogen beta chain 55,892 GTAGNALMDGASQLMGEN*R 42 0
IPI00298828 Beta-2-glycoprotein 38,273 VYKPSAGN*NSLYR 79 0
IPI00299729 Transcobalamin I 48,164 ADEGSLKN*ISIYTK 61 0
MN*DTIFGTMEER 59
IPI00300786 Salivary alpha-amylase 57,731 NVVDGQPFTNWYDN*GSNQVAFGR 112 13
IPI00333140 Delta-notch-like EGF repeat-
containing transmembrane
78,438 LVSFEVPQN*TSVK 52 0
IPI00335356 IGHM protein 60,966 GLTFQQN*ASSMCVPDQDTAIR 63 0
IPI00400826 Clusterin 57,796 LAN*LTQGEDQYYLR 96 0
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N-glycoproteins (Fig. 2a,b). Figure 2c shows the LC-
MS/MS spectrum of a formerly N-glycosylated peptide
GDQLILNLNN*ISSDR (where the asterisk denotes the site
of N-glycosylation) from Isoform 1 of long palate, lung,
and nasal epithelium carcinoma-associated protein 1 iden-
tified in whole saliva using the Sun method, whereas this
formerly N-glycopeptide was not detected in PA, SM, or SL
saliva (vide infra).
The seemingly poor overlap in protein identification
between the two methods could be attributed to several
factors. The method of collection of whole saliva has been
the same in both studies. However, the glycoprotein
pulldown experiments in our previous paper were per-
formed with saliva collected from only one subject [44]. In
this current study, saliva from five individual subjects was
pooled prior to carrying out the experiments. The identifi-
cation of proteins found exclusively using the Sun method
and not by the Zhang method could be explained by the
fact that in the latter method, the precipitated proteins were
resuspended in the coupling buffer. Some proteins may not
be readily soluble in this buffer and may have been lost in
the subsequent steps. Even for proteins that are solubilized
in the coupling buffer, carbohydrates may not be well
exposed, and oxidation and the ensuing agarose–hydrazide
coupling may be inefficient. The identification of peptides
exclusively by the Zhang method (and not by the Sun
method) could be because of the hydrophilic nature of
glycopeptides and their poor retention on the C18 columns.
However, we observed that the number of nonformerly
N-glycosylated peptides identified were fewer for the Sun
method compared to the Zhang method, i.e., the number
of nonglycosylated proteins binding to the resin was
reduced (Table 1). For the previous analysis of whole
saliva using the Zhang method, we measured 163 non-
glycosylated peptides. In the current study using the Sun
method, we detected only 14 nonglycosylated peptides in
whole saliva. This appears to be a significant advantage of
the N-glycopeptide capture method over the glycoprotein
capture.
Identification of N-Glycoproteins in Parotid, Submandibular,
and Sublingual Fluids To extend our catalogue of salivary
N-glycoproteins, we examined the salivary secretions of the
three main salivary glands: PA, SM, and SL. Whole saliva
is likely to include contributions from the salivary glands
and other sites in the oral cavity. Moreover, the collection
and processing of saliva from the PA, SM, and SL glands is
slightly different from whole saliva, as the stimulation of
secretion by the application of citric acid to the tongue was
not used, and the centrifugation of saliva to remove food
debris was not required. We applied the Sun method to
identify N-glycoproteins from PA, SM, and SL fluids. The
total number of formerly N-glycopeptides and the N-linked
glycoproteins they represent identified from PA, SM, and
SL fluids are 62/34 (peptides/protein), 80/44, and 98/53,
respectively (Tables 2, 3, and 4). A comparison of
glycoproteins isolated from the three glands is shown in
Fig. 3a,b. Only 42 formerly N-glycosylated peptides from
25 N-glycoproteins were found in all three glands. There
were a significant number of N-glycoproteins that were
unique to the saliva secretions of the individual glands.













IPI00418512 DMBT1 78,398 LVNLN*SSYGLCAGR 90 0
QADN*DTIDYSNFLTAAVSGGIIK 123
IPI00431645 HP protein 31,362 MVSHHN*LTTGATLINEQWLLTTAK 73 0
NLFLN*HSENATAK 44
VVLHPN*YSQVDIGLIK 104
IPI00478003 Alpha-2-macroglobulin 163,175 LGHIN*FTISTK 32 0
IPI00550991 Alpha-1-antichymotrypsin 50,596 FN*LTETSEAEIHQSFQHLLR 59 0
IPI00641229 Ig alpha-2 chain C region 53,868 LAGKPTHVN*VSVVMAEVDGTCY 92 1
LSLHRPALEDLLLGSEAN*LTCTLTGLR 96
IPI00553177 Alpha-1-antitrypsin 46,737 YLGN*ATAIFFLPDEGK 112 0
ADTHDEILEGLNFN*LTEIPEAQIHEGFQELLR 48
IPI00643034 Splice Isoform 1 of Phospholipid
transfer protein




a N* indicates the site of former N-linked glycosylation
bMascot score listed in parentheses
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Table 3 N-linked glycoproteins identified in submandibular salivary fluid
IPI accession
number




















IPI00010697 Isoform alpha-6X1X2B of
integrin alpha-6
126,539 EINSLN*LTESHNSR 31 0
IPI00011229 Cathepsin D 49,768 GSLSYLN*VTR 68 0
IPI00012887 Cathepsin L 37,540 YSVAN*DTGFVDIPKQEK 45 0
IPI00017601 Ceruloplasmin 122,128 EHEGAIYPDN*TTDFQR 63 0
IPI00022431 Alpha-2-HS-glycoprotein 39,300 AALAAFNAQNN*GSNFQLEEISR 41 0
IPI00022488 Hemopexin 51,643 ALPQPQN*VTSLLGCTH 27 0













IPI00031121 Carboxypeptidase E 53,117 DLQGNPIAN*ATISVEGIDHDVTSAK 49 0
GN*ETIVNLIHSTR 44
IPI00032292 Metalloproteinase inhibitor 1 23,156 FVGTPEVN*QTTLYQR 96 0
IPI00060143 Protein FAM3D 24,947 GLNIALVN*GTTGAVLGQK 73 0
IPI00166729 Alpha-2-glycoprotein 1, zinc 34,223 FGCEIENN*R 48 3
DIVEYYN*DSN*GSHVLQGR 66
IPI00168728 FLJ00385 protein (fragment) 56,111 EEQFN*STFR 51 0
IPI00171411 Golgi membrane protein 1 42,917 AVLVNN*ITTGER 70 0
IPI00178926 Immunoglobulin J chain 18,087 EN*ISDPTSPLR 59 0
IIVPLNNREN*ISDPTSPLR 77
IPI00218413 Biotinidase 61,093 NPVGLIGAEN*ATGETDPSHSK 58 0
IPI00242956 Fc fragment of IgG binding
protein




IPI00291410 Isoform 1 of long palate, lung,
and nasal epithelium carcinoma-
associated protein 1
52,408 DHN*ATSILQQLPLLSAMR 31 0
IPI00296099 Thrombospondin-1 129,300 VVN*STTGPGEHLR 70 0





49,100 LLAAAN*FTFK 74 0
LGATPVAMLHTNN*ATLR 68
SDDNLLN*TSALGR 56
IPI00297910 Tumor-associated calcium signal
transducer 2
35,687 HRPTAGAFN*HSDLDAELR 43 0
IPI00299729 Transcobalamin I 48,164 ADEGSLKN*ISIYTK 64 0
MN*DTIFGFTMEER 92
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formerly N-glycosylated peptide (LNAENN*ATFYFK, m/z
716.8) from splice isoform 1 of kininogen. This formerly
N-glycosylated peptide was found only in the PA fluid and
not in whole saliva, SM, or SL gland saliva. Figure 4b
shows the MS/MS spectrum of a triply charged peptide
(HYTN*SSQDVTVPCR, m/z 555.6) from the hypothetical
protein DKFZp686C02220. This formerly N-glycosylated
peptide was observed in SM saliva but not in whole saliva,
PA, or SL gland fluids.
Comparison of N-Glycoproteins in Whole Saliva and
Parotid, Submandibular, and Sublingual Fluids Whole
saliva is a complex mixture. It has contributions not only
from the three main salivary glands but also from other
minor salivary glands located in the mouth. Nonsalivary
secretions in whole saliva include gingival crevicular fluid,
bronchial and nasal secretions, and blood derivatives that
might enter the mouth by cuts or abrasions. Other












IPI00298828 Beta-2-glycoprotein 1 38,273 VYKPSAGN*NS 0
IPI00300786 Salivary alpha-amylase 57,731 NVVDGQPFTNWYDN*GSNQVAFGR 79 6
IPI00304557 Short palate, lung, and nasal
epithelium carcinoma associated
protein 2
26,995 GLNLSFPVTAN*VTVAGPIIGQIINLK 84 2
IPI00328460 Transmembrane protease, serine
11B
46,235 MLNAFQNSSIYK 64 0
LLPNAN*GSNVQLQLK 80
IPI00328960 Similar to LOC147645 protein 91,568 FVTAGSN*VTLR 69 0
IPI00333140 Delta-notch-like EGF repeat-
containing transmembrane
78,438 LVSFEVPQN*TSVK 48 0
IPI00335356 IGHM protein 64,998 GLTFQQN*ASSMCVPDQDTAIR 60 0
IPI00374315 Hypothetical LOC389429 37,902 IILN*QTAR 63 0
IPI00384872 UDP-glucuronosyltransferase 1–7 59,779 YTGTRPSNLAN*NTILVK 46 0
IPI00400826 Clusterin 57,796 LAN*LTQGEDQYYLR 81 0








54,126 HYTN*SSQDVTVPCR 55 0
IPI00431645 HP protein 45,177 NLFLN*HSENATAK 39 0
VVLHPN*YSQVDIGLIK 57
IPI00550991 Alpha-1-antichymotrypsin 50,566 YTGN*ASALFILPDQDK 36 0









IPI00643034 Splice isoform 1 of phospholipid
transfer protein
54,705 VSN*VSCQASVSR 90 0
IYSN*HSALESLALIPLQAPLK 64
IPI00855918 Mucin 5, subtype B,
tracheobronchial










a N* indicates the site of former N-linked glycosylation
bMascot score listed in parentheses
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Table 4 N-linked glycoproteins identified in sublingual salivary fluid
IPI accession
number








IPI00000877 Hypoxia-upregulated protein 111,266 VFGSQN*LTTVK 79 0
LSALDNLLN*HSSMFLK 63
IPI00002818 Isoform 1 of kallikrein 11 27,448 CAN*ITIIEHQK 36 0












IPI00010697 Isoform alpha-6X1X2B of
integrin alpha-6
41,000 EIN*SLN*LTESHNSR 32 0
IPI00011229 Cathepsin D 44,524 GSLSYLN*VTR 68 0
IPI00021891 Splice isoform 1 of fibrinogen
gamma chain
51,549 DLQSLEDILHQVEN*K 46 0
VDKDLQSLEDILHQVEN*K 58
IPI00022229 Apolipoprotein B-100 515,241 FVEGSHN*STVSLTTK 29 0
IPI00022431 Alpha-2-HS-glycoprotein 39,300 AALAAFNAQNN*GSNFQLEEISR 104 0
IPI00022463 Serotransferrin 77,000 QQQHLFGSN*VTDCSGNFCLFR 82 0
CGLVPVLAENYN*K 43
IPI00022488 Hemopexin 51,643 ALPQPQN*VTSLLGCTH 63 0
IPI00022974 Prolactin-inducible protein 16,562 TFYWDFYTN*R 43 0








IPI00025846 Splice isoform 1 of
desmocollin-2
99,899 NGIYN*ITVLASDQGGR 65 0
AN*YTILK 32
IPI00027192 Procollagen-lysine 83,497 EQIN*ITLDHR 38 0
IPI00030847 Transmembrane 9 superfamily
protein member 3
67,843 IVDVN*LTSEGK 60 0
IPI00031121 Carboxypeptidase E 53,117 GN*ETIVNLIHSTR 44 0
IPI00031547 Desmoglein 3 107,435 LPAVWSITTLN*ATSALLR 80 0
IPI00032258 Complement C4 192,650 GLN*VTLSSTGR 55 0
IPI00032292 Metalloproteinase inhibitor 1 23,156 FVGTPEVN*QTTLYQR 87 0
IPI00060143 Protein FAM3D 24,947 GLNIALVN*GTTGAVLGQK 116 0
IPI00166729 Alpha-2-glycoprotein 1, zinc 34,223 FGCEIENN*R 50 0
IPI00168728 FLJ00385 protein (fragment) 56,111 EEQFN*STFR 51 0
IPI00171411 Golgi membrane protein 1 49,768 AVLVNN*ITTGER 89 0
LQQDVLQFQKN*QTNLER 43
IPI00178926 Immunoglobulin J chain 18,087 IIVPLNNREN*ISDPTSPLR 62 0
EN*ISDPTSPLR 55
IPI00242956 IgGFc binding protein 571,718 LLISSLSESPASVSILSQADN*TSKK 40 0
VTVRPGESVMVN*ISAK 47
IPI00291410 Isoform 1 of long palate, lung,
and nasal epithelium
carcinoma-associated protein 1
54,878 DHN*ATSILQQLPLLSAMR 46 0
IPI00295105 Carbonic anhydrase VI 35,343 GLN*MTGYETQAGEFPMVNN
GHTVQIGLPSTMR
39 0
IPI00296099 Thrombospondin 1 129,330 VVNSTTGPGEHLR 73 0














49,100 LLAAAN*FTFK 72 0
LGATPVAMLHTNN*ATLR 66
IPI00297910 Tumor-associated calcium signal
transducer 2
35,687 HRPTAGAFN*HSDLDAELR 65 0
IPI00298082 Calcium-activated chloride
channel protein 2
101,288 AAN*SSVPPITVNAK 44 0
HSN*GSYSAFGER 51
DSFDDALQVN*TTDLSPK 67
IPI00298828 Beta-2-glycoprotein I 38,273 VYKPSAGN*NSLYR 79 0
IPI00299729 Transcobalamin I 48,164 ADEGSLKN*ISIYTK 73 0
MN*DTIFGFTMEER 96
IPI00300786 Salivary alpha-amylase 57,731 NVVDGQPFTNWYDN*GSNQVAFGR 93 1
IPI00303333 Platelet receptor GI24 33,901 HGLESASDHHGN*FSITMR 41 0
IPI00304557 Short palate, lung, and nasal
epithelium carcinoma
associated protein 2
26,995 GLN*LSFPVTAN*VTVAGPIIGQIINLK 82 2
IPI00328460 Transmembrane protease, serine
11B
46,235 LLPNAN*GSNVQLQLK 83 0
MLNAFQN*SSIYK 59
IPI00328960 Predicted: hypothetical protein
XP_085831
91,568 FVTAGSN*VTLR 50 0
IPI00332845 Leucine-rich repeats and
calponin homology (CH)
domain containing 2
69,610 KLPPGLLAN*FTLLR 77 0
IPI00335356 IGHM protein 49,526 GLTFQQN*ASSMCVPDQDTAIR 47 0
IPI00374315 Uncharacterized protein C6orf58 37,902 IILN*QTAR 62 0
IPI00384872 UDP-glucosyltransferase 1–7 59,779 YTGTRPSNLAN*NTILVK 33 0
IPI00400826 Clusterin 57,796 LAN*LTQGEDQYYLR 58 0
MLN*TSSLLEQLNEQFNWVSR 99




149,965 QGN*GTFVQTDKPLYTPGQQVYFR 72 0
LGHIN*FTISTK 39
HSN*GSYSAFGER 51
IPI00431645 HP protein 31,362 VVLHPN*YSQVDIGLIK 53 0
NLFLN*HSEN*ATAK 41
IPI00550991 Alpha-1-antichymotrypsin 50,596 FN*LTETSEAEIHQSFQHLLR 58 0
IPI00641229 Ig alpha-2 chain C region 53,868 LAGKPTHVN*VSVVMAEVDGTCY 97 3
LSLHRPALEDLLLGSEAN*LTCTLTGLR 104
IPI00553177 Alpha-1-antitrypsin 46,737 ADTHDEILEGLNFN*LTEIPEAQIHEGFQELLR 51 0
YLGN*ATAIFFLPDEGK 101
IPI00643034 Splice isoform 1 of phospholipid
transfer protein




IPI00855918 Mucin 5, subtype B,
tracheobronchial










a N* indicates the site of former N-linked glycosylation
bMascot score listed in parentheses
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bacteria, fungi, and viruses, food, and other extrinsic
substances and from the lining of the mouth [51]. It is
expected that the glycoprotein profile will differ between
that of whole saliva and PA, SM, and SL saliva. A total of
83 formerly N-glycosylated peptides from 46 N-glycopro-
teins were found to be common in whole saliva and PA,
SM, and SL fluids combined. Thirty-nine formerly N-
glycosylated peptides from 16 N-glycoproteins were unique
to whole saliva, and 34 formerly N-glycosylated peptides
from 15 N-glycoproteins were found in PA, SM, or SL and
not detected in whole saliva (Fig. 5a,b). Of the glycopro-
teins that were unique to whole saliva and not found in PA,
SM, and SL fluids, three proteins were not detected in our
previous global proteome analysis of PA, SM, and SL
fluids [52]. These proteins include lumican precursor,
complement component C9, and cystatin-related epididy-
mal spermatogenic protein. Of these, complement compo-
nent C9 has been detected in whole saliva in our previous
studies (unpublished data), but the other two proteins were
not detected previously in our global whole-saliva proteome
analysis. Table 5 is a combined listing of all the salivary N-
glycoproteins identified. The detection of N-glycoproteins
that are unique to whole saliva is not surprising because
whole saliva is a mixture of various components. Some
(a) (b)Glycopeptides GlycoproteinsFig. 3 Comparison of a former-
ly N-glycosylated peptides and
the b N-glycoproteins they
represent identified in PA, SM,
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Fig. 4 MS/MS mass spectra of
a doubly charged peptide,
LNAENN*ATFYFK (m/z
716.8; asterisk denotes the site
of N-glycosylation) from splice
isoform 1 of kininogen from
parotid fluid, and b triply
charged peptide,
HYTN*SSQDVTVPCR (m/z
555.6) from hypothetical protein
DKFZp686C02220 from
submandibular fluid
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glycoproteins detected in whole saliva may not originate
from the salivary glands. Additionally, some proteins
originating from the salivary glands may have undergone
posttranslational modifications after being secreted into the
oral cavity. These formerly glycosylated peptides are
observed only in whole saliva. However, the detection of
N-glycoproteins unique to PA, SM, and SL saliva is
somewhat surprising. It may be explained by the fact that
the glycosylation might have been lost upon secretion into
the mouth by the action of enzymes. Whole saliva has a
plethora of oral bacteria that secrete enzymes to deglyco-
sylate glycoproteins to alter the properties of the protein
altogether or to utilize the sugars for their growth [14].
Glycoproteins from the salivary glands may be also
sufficiently diluted in whole saliva, so that they fall below
the detection limit of our glycoprotein pulldown method. It
is also possible that these set of glycoproteins are secreted
only upon stimulation of the glands and not otherwise.
A gene ontology (GO) analysis of the N-glycoproteins
identified in saliva to categorize them according to their
cellular location, function, and processes is shown in Fig. 6.
The majority of the N-glycoproteins are extracellular (40%;
Fig. 6a). Several identified N-glycoproteins were annotated
as membrane proteins (14%). Liu and coworkers employed
the similar hydrazide chemistry to analyze the human
plasma N-glycoproteome and observed a similar trend
[42]; the majority of the plasma N-glycoproteins are
extracellular or plasma membrane proteins. However,
nuclear, cytoplasmic, or cytoskeletal proteins were not
identified in the plasma N-glycoprotein study, whereas in
our study of salivary proteins, we observed proteins from
the nucleus, cytoplasm, and cytoskeleton. Figure 6b shows
the GO distribution of salivary glycoproteins based on their
functions. Fifty-one percent of the glycoproteins identified
are involved in binding, a trend observed also in the
analysis of plasma N-glycoproteins [42]. A large number of
salivary N-glycoproteins also showed catalytic activity and
also a role in enzyme regulation. Salivary N-glycoproteins are
involved in catalytic functions such as peptidase, nuclease,
hydrolase, and transferase activities. N-Glycoproteins
detected in whole saliva are also involved in biological
processes such as metabolism, transport, response to stimuli,
response to stress, and signal transduction.
Discussion
The glycoprotein pulldown method using agarose–hydrazide
is an efficient technique for identifying N-linked glycopro-
teins in complex mixtures. We employed this method to
study the whole salivary N-glycoproteome by the Zhang
method [41, 44] and the Sun method [46]. This aided us to
extend our list of whole-salivary N-glycoproteins that may
not have been achieved by the application of one method
alone. In our study of N-glycoproteins in whole saliva,
several proteins were identified by the Zhang method that
were not identified by the Sun method and vice versa.
In this current study, we attempted to probe deeper into
the salivary proteome and extend the N-glycoprotein list by
examining not only whole saliva but PA, SM, and SL
fluids. Combining data sets obtained from whole saliva, PA,
SM, and SL saliva, we measured 148 sites of N-linked
glycosylation to date. Larsen et al. reported 97 sites of N-
linked glycosylation in whole saliva [40]. An overlap of 62
sites of N-glycosylation was found in a comparison of the
two studies. In a comparison of N-glycoproteins in whole
saliva versus PA, SM, and SL saliva, a large number of N-
glycoproteins were identified in PA, SM, and SL saliva that
were not found in whole saliva and vice versa. In our study,
15 N-glycoproteins were detected in PA, SM, or SM saliva
and were not found in whole saliva.
In this study, we report isolation of glycoproteins from
the fluids from the SM and SL glands separately. The SM
and SL glands are both located below the tongue. It was
earlier believed that it is difficult to segregate the two
fluids, as they often share a common salivary duct to empty
the contents of the gland into the oral cavity [53]. However,
other studies have shown that many individuals have
separate salivary ducts for the two glands, and it is possible
to collect secretions from SM and SL separately [54]. Many
new devices have been fabricated that make the collection
WS PA/SM/SL
39 83 34 16 46 15
WS PA/SM/SL
(a) (b)  Glycopeptides   GlycoproteinsFig. 5 Comparison of a former-
ly N-glycosylated peptides and
the b N-glycoproteins they
represent identified in whole
saliva and PA, SM, and SL
fluids combined
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Table 5 Combined list of all N-Glycoproteins identified in human salivary fluids
IPI accession
number






WS PA SM SL
IPI00000877 Hypoxia-upregulated protein 111,266 VFGSQN*LTTVK 510–520 No No No Yes
LSALDNLLN*HSSMFLK 822–837 No No No Yes
IPI00002818 Splice isoform 1 of kallikrein 11 27,448 CAN*ITIIEHQK 163–173 Yes No No Yes
IPI00003351 Extracellular matrix protein 1 60,635 HIPGLIHN*MTAR 437–448 Yes No Yes Yes
IPI00004573 Polymeric-immunoglobulin receptor 83,262 VPGN*VTAVLGETLK 466–479 Yes Yes Yes Yes
WN*NTGCQALPSQDEGPSK 498–515 Yes Yes Yes Yes
IIEGEPNLKVPGN*VTAVLGETLK 457–479 Yes Yes Yes Yes
GLSFDVSLEVSQGPGLLN*DTK 118–138 No Yes No Yes
LSLLEEPGN*GTFTVILNQLTSR 413–434 Yes Yes Yes Yes
VPGN*VTAVLGETLKVPCHFPCK 466–487 Yes Yes Yes Yes
QIGLYPVLVIDSSGYVNPN*YTGR 168–190 Yes Yes Yes Yes
AN*LTNFPEN*GTFVVNIAQLS
QDDSGR
82–107 Yes Yes Yes Yes
IPI00007244 Myeloperoxidase 83,815 SCPACPGSN*ITIR 315–327 Yes No Yes No
SYN*DSVDPR 481–489 Yes No No No
IPI00010697 Isoform alpha 6X1X2B of integrin
alpha-6
126,539 EINSLN*LTESHNSR 925–938 No No Yes No
IPI00011229 Cathepsin D 49,768 GSLSYLN*VTR 257–266 Yes Yes Yes Yes
IPI00855918 Mucin 5, subtype B,
tracheobronchial
590,122 VVLLDPKPVAN*VTCVNK 4,977–4,993 Yes No Yes Yes
AQGLVLEASN*GSVLINGQR 136–154 Yes No Yes Yes
GN*CTYVLMR 5,036–5,044 Yes No Yes Yes
AFGQFFSPGEVIYN*K 4,888–4,902 Yes No Yes Yes
AFGQFFSPGEVIYN*KTDR 4,888–4,905 Yes No Yes Yes
DIECQAESFPN*WTLAQVGQK 1,547–1,567 Yes No Yes Yes
QVNETWTLEN*CTVAR 4,956–4,970 Yes No Yes Yes
LDGPTEQCPDPLPLPAGN*
CTDEEGICHR
237–264 Yes No Yes Yes
FGN*LSLYLDNHYCTASATAAAAR 5,054–5,076 No No No Yes
LPYSLFHN*NTEGQCGTCTNNQR 5,153–5,172 No No No Yes
IPI00012887 Cathepsin L 37,540 YSVAN*DTGFVDIPK 217–230 Yes Yes Yes No
IPI00013972 Carcinoembryonic antigen-related
cell adhesion molecule 8
LFIPN*ITTK 284–292 Yes No No No
IPI00017601 Ceruloplasmin 122,128 EN*LTAPGSDSAVFFEQGTTR 396–415 No Yes No No
EHEGAIYPDN*TTDFQR 129–144 No Yes Yes No
IPI00019943 Afamin 69,024 DIENFN*STQK 28–37 Yes No No No
IPI00020091 Alpha-1-acid glycoprotein 2 23,588 QNQCFYN*SSYLNVQR 87–101 Yes No No No
IPI00020487 Extracellular glycoprotein lacritin 14,237 QFIEN*GSEFAQK 115–126 Yes No No No
IPI00020986 Lumican 38,405 LHINHNN*LTESVGPLPK 121–137 Yes No No No
IPI00021891 Splice isoform 1 of fibrinogen
gamma chain
51,479 VDKDLQSLEDILHQVEN*K 62–79 Yes Yes No Yes
DLQSLEDILHQVEN*K 65–79 Yes No No Yes
IPI00022229 Apolipoprotein B-100 515,241 FVEGSHN*STVSLTTK 3,405–3,419 No No No Yes
IPI00022395 Complement component C9 63,133 AVN*ITSENLIDDVVSLIR 413–430 Yes No No No
IPI00022417 Leucine-rich alpha-2-glycoprotein 38,944 KLPPGLLAN*FTLLR 178–191 Yes Yes No Yes
IPI00022429 Alpha-1-acid glycoprotein 1 2,477 QDQCIYN*TTYLNVQR 87–101 Yes No No No
IPI00022431 Alpha-2-HS-glycoprotein 39,300 AALAAFNAQNN*GSNFQLEEISR 166–187 Yes Yes Yes Yes
VCQDCPLLAPLN*DTR 145–159 Yes Yes No No
IPI00022463 Serotransferrin 77,000 QQQHLFGSN*VTDCSGNFCLFR 622–642 Yes Yes No Yes
CGLVPVLAENYN*K 421–433 Yes Yes No Yes
IPI00022488 Hemopexin 51,643 ALPQPQN*VTSLLGCTH 747–762 Yes Yes Yes Yes
SWPAVGN*CSSALR 181–193 Yes No No No
IPI00643034 Splice isoform 1 of phospholipid
transfer protein
54,705 VSN*VSCQASVSR 141–152 No Yes Yes Yes
GAFFPLTERN*WSLPNR 236–244 No Yes No Yes
IYSN*HSALESLALIPLQAPLK 395–415 No Yes Yes Yes
GKEGHFYYN*ISEVK 56–69 No Yes No Yes










WS PA SM SL
IPI00022974 Prolactin-inducible protein 16,562 TFYWDFYTN*R 97–106 Yes No No Yes
IPI00023673 Galectin-3 binding protein 65,289 ALGFEN*ATQALGR 64–76 Yes Yes Yes Yes
EPGSN*VTMSVDAECVPMVR 188–206 Yes No Yes No
YKGLN*LTEDTYKPR 394–405 Yes Yes No Yes
GLN*LTEDTYKPR 396–407 Yes Yes Yes Yes
AAIPSALDTN*SSK 542–554 Yes Yes Yes Yes
TVIRPFYLTN*SSGVD 571–585 Yes No No No
IPI00025023 Lactoperoxidase 80,237 ASLTN*VTDPSLDLTSLSLEV
GCGAPAPVVR
102–131 No Yes Yes Yes
IVGYLNEEGVLDQN*R 199–213 Yes Yes Yes Yes
LRN*LSSPLGLMAVNQEVSDHG
LPYLPYDSK
320–349 Yes Yes Yes Yes
KPSPCEFIN*TTAR 350–362 Yes Yes Yes Yes
IPI00025753 Desmoglein 1 113,644 TGEIN*ITSIVDR 106–117 Yes No No No
IPI00025846 Splice isoform 1 of desmocollin-2 99,899 NGIYN*ITVLASDQGGR 542–557 Yes No No Yes
AN*YTILK 391–397 Yes No No Yes
AN*YTILKGNENGNFK 391–405 Yes No No No
LKAIN*DTAAR 625–634 Yes No No No
IPI00027192 Procollagen-lysine 83,497 EQIN*ITLDHR 194–203 No No No Yes
IPI00027486 Carcinoembryonic antigen-related
cell adhesion molecule 5
76,748 TLTLFN*VTR 555–563 Yes No No No
IPI00030847 Transmembrane 9 superfamily
protein member 3
67,843 IVDVN*LTSEGK 170–180 No No No Yes
IPI00031019 Cystatin-related epididymal
spermatogenic protein
16,265 KLKPVN*ASNANVK 34–46 Yes No No No
IPI00031121 Carboxypeptidase E 53,117 GN*ETIVNLIHSTR 138–150 Yes No Yes Yes
DLQGNPIAN*ATISVEGIDHDVTSAK 382–406 Yes No Yes No
IPI00031547 Desmoglein 3 107,435 NTGDIN*ITAIVDR 105–117 Yes No No No
DSTFIVN*K 453–460 Yes No No No
LPAVWSITTLN*ATSALLR 535–552 Yes No No Yes
IPI00032258 Complement C4 192,650 GLN*VTLSSTGR 1,326–1,336 Yes Yes No Yes
IPI00032292 Metalloproteinase inhibitor 1 23,156 FVGTPEVN*QTTLYQR 46–60 Yes Yes Yes Yes
IPI00032328 Splice Isoform 1 of kininogen 71,900 LNAENN*ATFYFK 289–300 No Yes No No
IPI00060143 Protein FAM3D 24,947 GLNIALVN*GTTGAVLGQK 100–117 Yes No Yes Yes
IPI00166729 Alpha-2-glycoprotein 1, zinc 34,223 DIVEYYNDSN*GSHVLQGR 100–117 Yes No Yes No
FGCEIENN*R 118–126 Yes No Yes Yes
FGCEIENN*RSSGAFWK 118–133 Yes No No No
IPI00171411 Golgi membrane protein 1 49,768 AVLVNN*ITTGER 113–124 Yes No Yes Yes
LQQDVLQFQKN*QTNLER 143–152 Yes No No Yes
IPI00178926 Immunoglobulin J chain 18,087 EN*ISDPTSPLR 70–80 Yes Yes Yes Yes
IIVPLNNREN*ISDPTSPLR 62–80 Yes Yes Yes Yes
IPI00218413 Biotinidase 61,093 NPVGLIGAEN*ATGETDPSHSK 320–340 No No Yes No
IPI00218460 Splice isoform 3 of attractin 158,537 IDSTGN*VTNELR 411–422 Yes No No No
IPI00242956 Fc fragment of IgG binding protein 571,718 LLISSLSESPASVSILSQADN*TSK 55–78 No No Yes No
LLISSLSESPASVSILSQADN*TSKK 55–79 No No No Yes
VTVRPGESVMVN*ISAK 78–95 Yes No Yes Yes
KVTVRPGESVMVN*ISAK 79–95 Yes No No No
VVTVAALGTN*ISIHKDEIGK 1,734–1,748 Yes No Yes No
VITVQVAN*FTLR 2,511–2,522 Yes No Yes No
YLPVN*SSLLTSDCSER 5,182–5,197 Yes No No No
IPI00400826 Clusterin 57,796 LAN*LTQGEDQYYLR 424–437 Yes Yes Yes Yes
MLN*TSSLLEQLNEQFNWVSR 352–364 No Yes No Yes










WS PA SM SL
IPI00291410 Isoform 1 of long palate, lung, and
nasal epithelium carcinoma-
associated protein 1
54,878 DHN*ATSILQQLPLLSAMR 46–65 Yes Yes Yes Yes
GDQLILNLNN*ISSDR 392–406 Yes No No No
IPI00291488 Splice isoform of WAP four-
disulfile core domain protein 2
12,984 TGVCPELQADQN*CTQECV
SDSECADNLK
33–60 Yes No No No
IPI00295105 Carbonic anhydrase VI 35,343 LENSLLDHRN*K 247–257 Yes No No No
GLN*MTGYETQAGEFPMVNNGH
TVQIGLPSTMR
65–96 No Yes Yes Yes
IPI00296099 Thrombospondin 1 129,330 VVN*STTGPGEHLR 1,065–1,077 Yes Yes Yes Yes
IPI00296654 Bactericidal/permeability-increasing
protein-like 1
49,100 LGATPVAMLHTNN*ATLR 320–336 Yes Yes Yes Yes
LLAAAN*FTFK 91–100 Yes No Yes Yes
SDDNLLN*TSALGR 287–299 Yes No Yes No
IPI00297910 Tumor-associated calcium signal
transducer 2
35,687 HRPTAGAFN*HSDLDAELR 160–177 Yes No Yes Yes
IPI00298082 Calcium activates chloride channel
protein 2
101,288 AAN*SSVPPITVNAK 586–559 No No No Yes
DSFDDALQVN*TTDLSPK 802–818 Yes No No Yes
N*VSILIPENWK 75–85 No No No Yes
IPI00298237 Tripeptidyl-peptidase I 61,708 FLSSSPHLPPSSYFN*ASGR 429–447 Yes No No No
IPI00298497 Fibrinogen beta chain 55,892 GTAGNALMDGASQLMGEN*R 377–395 No Yes No No
IPI00298828 Beta-2-glycoprotein I 38,273 VYKPSAGN*NSLYR 155–167 Yes Yes Yes Yes
LGN*WSAMPSCK 251–261 Yes No No No
IPI00299547 Neutrophil gelatinase-associated
lipocalin
22,774 EDKSYN*VTSVLFR 64–76 Yes No No No
SYN*VTSVLFR 83–92 Yes No No No
IPI00299729 Transcobalamin I 48,164 ADEGSLKN*ISIYTK 209–222 Yes Yes Yes Yes
MN*DTIFGFTMEER 368–380 Yes Yes Yes Yes
N*ISIYTK 216–222 No No Yes Yes
AQKMN*DTIFGFTMEER 365–380 Yes No No No
IPI00300786 Salivary alpha-amylase 57,731 NVVDGQPFTNWYDN*
GSNQVAFGR
414–436 Yes Yes Yes Yes





122–147 Yes No Yes Yes
AEPIDDGKGLN*LSFPVTAN*
VTVAGPIIGQIINLK
114–147 Yes No No No
IPI00553177 Alpha-1-antitrypsin 46,737 YLGN*ATAIFFLPDEGK 268–283 Yes Yes Yes Yes
ADTHDEILEGLNFN*LTEIPEA
QIHEGFQELLR
94–125 No Yes Yes Yes
IPI00303333 Platelet receptor GI24 33,901 HGLESASDHHGN*FSITMR 117–134 No No No Yes
IPI00328460 Transmembrane protease, serine
11B
46,235 MLNAFQN*SSIYK 81–92 No No Yes Yes
LLPNAN*GSNVQLQLK 102–116 No No Yes Yes
IPI00328960 Similar to carcinoembryonic
antigen-related cell adhesion
molecule 1
91,568 FVTAGSN*VTLR 427–437 Yes No Yes Yes
TPASN*ISTQVSHTK 140–153 Yes No No No
IPI00332845 Leucine-rich repeats and calponin
homology (CH) domain
containing 2
69,610 MLTYLN*ISR 158–166 No No No Yes
KLPPGLLAN*FTLLR 178–191 No No No Yes
IPI00333140 Delta-notch-like EGF repeat-
containing transmembrane
78,438 LVSFEVPQN*TSVK 215–256 Yes Yes Yes No
IPI00335356 IGHM protein 49,526 GLTFQQN*ASSMCVPDQDTAIR 354–374 Yes Yes Yes Yes
IPI00374315 Hypothetical LOC389429 37,902 IILN*QTAR 66–73 Yes No Yes Yes
MGMYKIILN*QTAR 61–73 Yes No No No
IPI00384872 UDP-glucuronosyltransferase 1–7 59,779 YTGTRPSNLAN*NTILVK 334–350 No No Yes Yes
IPI00641229 Ig alpha-2 chain C region 55,715 LAGKPTHVN*VSVVMAEVDGTCY 319–340 Yes Yes Yes Yes
LSLHRPALEDLLLGSEAN*
LTCTLTGLR
114–140 Yes Yes Yes Yes
100 Clin Proteom (2008) 4:80–104
of segregated SM and SL saliva easier [50, 55]. Hu and
coworkers found markers that clearly differentiate SM from
SL saliva. They found cystatin C to be a specific marker for
SM saliva and Muc5B and calgranulin B for SL saliva [56].
During the course of collection of SM and SL saliva for our
experiments, calgranulin B was employed as a marker to
ensure purity of the segregated samples. Cystatin C and
calgranulin B have no sites of N-linked glycosylation and
were thus not detected by our method. However, Muc5B
has several known and putative sites of N-glycosylation. In
our current study, we found formerly N-glycosylated










WS PA SM SL
TPLTAN*ITK 200–208 Yes No Yes No
IPI00418512 DMBT1 259,409 LVNLN*SSYGLCAGR 998–1,111 Yes Yes Yes Yes
QADN*DTIDYSNFLTAAVSGGIIK 1,298–1,320 Yes Yes Yes Yes
CSGN*ESYLWSCPHK 822–835 Yes No No No
IPI00419164 Alpha-2-macroglobulin like
protein 1
149,965 LGHIN*FTISTK 863–873 Yes No Yes Yes
QGN*GTFVQTDKPLYTPGQQVYFR 118–140 No No Yes Yes
HSN*GSYSAFGER 1,018–1,029 No No No Yes
IPI00423461 Hypothetical protein
DKFZp686C02220
54,126 HYTN*SSQDVTVPCR 249–262 No No Yes No
IPI00431645 HP protein 31,362 MVSHHN*LTTGATLINEQWLLTTAK 54–77 Yes Yes No No
NLFLN*HSEN*ATAK 78–90 Yes Yes Yes Yes
VVLHPN*YSQVDIGLIK 170–186 Yes Yes Yes Yes
IPI00168728 FLJ00385 protein (fragment) 56,111 EEQFN*STFR 285–294 Yes Yes Yes Yes
IPI00550991 Alpha-1-antichymotrypsin 50,596 FN*LTETSEAEIHQSFQHLLR 190–219 No Yes No Yes
YTGN*ASALFILPDQDK 293–308 No No Yes No
a N* indicates the site of former N-linked glycosylation
































Fig. 6 Gene ontology analysis
of the a cellular distribution
and b cellular functional
distribution of N-glycoproteins
identified in salivary fluids
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number of Muc5B peptides in SL compared to SM; a total
of ten formerly N-glycosylated peptides were found in SL
and only eight in SM. Hu et al. found no peptides from
Muc5B in SM saliva in their shotgun protein identification
experiments. However, we did find differences in the
overall N-glycoprotein profile between SM and SL saliva
(Fig. 3). As a result, we believe that collection of
segregated SM and SL fluids can be accomplished and
their salivary proteomes can be differentiated.
Studies on the salivary glycoproteins have potential
implications on salivary biomarker discovery efforts, as
saliva is gaining popularity as a diagnostic fluid for disease
markers. Many attempts have been made in the past few
years to use saliva to discover biomarkers for diseases
localized in the oral cavity or in the head/neck region. Some
diseases for which saliva has been used as a medium for
biomarker discovery include oral cancer squamous cell
carcinoma [57–65], head and neck squamous cell carcino-
ma [66–68], and Sjogren’s syndrome [69–77]. In addition,
saliva has shown promise for use in the detection of many
nonoral (i.e., nonproximal) systemic diseases. In patients
with breast cancer, elevated levels of C-erb2 and CA15-3
have been detected in saliva of cancer patients versus
control subjects [78–80]. Antibodies to the human immu-
nodeficiency virus (HIV) have been found in saliva of HIV-
positive patients; saliva-based HIV tests are now gaining
popularity [81]. We believe our studies on N-glycoproteins
in whole saliva will benefit future work on disease
biomarker discovery.
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